Ray KK, Nicholls SJ, Buhr KA, et al. - In this randomized, double-blind, placebo-controlled trial involving patients with recent acute coronary syndrome (preceding 7 to 90 days), type 2 diabetes, and low high-density lipoprotein cholesterol levels, researchers investigated whether apabetalone significantly decreases major adverse cardiovascular events. The study was conducted at 190 sites in 13 countries. Participants were randomized (1:1) to receive either apabetalone 100 mg orally twice daily (n = 1,215) or matching placebo (n = 1,210) in addition to standard care. A composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke was considered as the primary outcome. According to the findings, no significant reduction in the risk of major adverse cardiovascular events was brought about by apabetalone added to standard therapy in this patient population.